Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
Open Access
- 1 July 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 82 (1), 129-138
- https://doi.org/10.1007/s00280-018-3597-5
Abstract
Alectinib is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor that is active in the central nervous system (CNS). Alectinib demonstrated robust efficacy in a pooled analysis of two single-arm, open-label phase II studies (NP28673, NCT01801111; NP28761, NCT01871805) in crizotinib-resistant ALK-positive non-small-cell lung cancer (NSCLC): median overall survival (OS) 29.1 months (95% confidence interval [CI]: 21.3-39.0) for alectinib 600 mg twice daily (BID). We investigated exposure-response relationships from final pooled phase II OS and safety data to assess alectinib dose selection. A semi-parametric Cox proportional hazards model analyzed relationships between individual median observed steady-state trough concentrations (C (trough,ss)) for combined exposure of alectinib and its major metabolite (M4), baseline covariates (demographics and disease characteristics) and OS. Univariate logistic regression analysis analyzed relationships between C (trough,ss) and incidence of adverse events (AEs: serious and Grade ae 3). Overall, 92% of patients (n = 207/225) had C (trough,ss) data and were included in the analysis. No statistically significant relationship was found between C (trough,ss) and OS following alectinib treatment. The only baseline covariates that statistically influenced OS were baseline tumor size and prior crizotinib treatment duration. Larger baseline tumor size and shorter prior crizotinib treatment were both associated with shorter OS. Logistic regression confirmed no significant relationship between C (trough,ss) and AEs. Alectinib 600 mg BID provides systemic exposures at plateau of response for OS while maintaining a well-tolerated safety profile. This analysis confirms alectinib 600 mg BID as the recommended global dose for patients with crizotinib-resistant ALK-positive NSCLC.Keywords
Funding Information
- F. Hoffmann-La Roche
This publication has 39 references indexed in Scilit:
- Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistanceCancer Letters, 2014
- Determining the optimal dose in the development of anticancer agentsNature Reviews Clinical Oncology, 2014
- Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012Published by American Medical Association (AMA) ,2014
- Isolated central nervous system progression on Crizotinib An Achilles heel of non-small cell lung cancer with EML4-ALK translocation?Cancer Biology & Therapy, 2012
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 2012
- Pharmacokinetic/Pharmacodynamic Modeling of Crizotinib for Anaplastic Lymphoma Kinase Inhibition and Antitumor Efficacy in Human Tumor Xenograft Mouse ModelsThe Journal of pharmacology and experimental therapeutics, 2011
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor CrizotinibJournal of Clinical Oncology, 2011
- Targeting Anaplastic Lymphoma Kinase in Lung CancerClinical Cancer Research, 2011
- EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK InhibitorsNew England Journal of Medicine, 2010
- Clinical Pharmacokinetics of Therapeutic Monoclonal AntibodiesClinical Pharmacokinetics, 2010